Kelman to head new Novartis OTC division

Joins from Johnson & Johnson

Naomi Kelman has been appointed head of the Novartis OTC division, reporting to Joseph Jimenez, chief executive of Novartis.

Kelman joins the Swiss company from Johnson & Johnson where she has held several roles within the consumer and medical device and diagnostic sectors.

‘With the upcoming Alcon merger, we have decided to put additional focus on two important businesses which today comprise the Consumer Health Division: OTC and Animal Health, by streamlining and simplifying our decision making process,’ said Jimenez. ‘We look forward to Naomi joining our leadership team – her experience in consumer businesses, combined with her drive for results make her well suited to run our OTC business.’

George Gunn becomes head of Animal Health.

The Novartis OTC and Animal Health businesses will become separate Novartis divisions, in addition to the Pharmaceuticals, Sandoz (generics), Vaccines & Diagnostics Divisions.

Following the completion of the merger of Novartis and Alcon, CIBA Vision and Novartis ophthalmic medicines will be merged into the new Alcon eye care division of Novartis.

Until the close of the Alcon transaction, George Gunn will continue to manage the CIBA Vision business.

You may also like

Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Manufacturing

Novartis opens facility for innovative cell and gene therapies in Switzerland

New building in Stein also hosts the production of difficult-to-manufacture solid dosage forms
Finance

Lonza to buy sterile drug product fill-finish facility from Novartis

Swiss CDMO bids to keep management and operations teams and manufacture for Novartis at the site in Stein
Regulatory

Novartis starts voluntary recall after peanut contamination scare

Three lots of Promacta 12.5 mg for oral suspension to the consumer level have been recalled due to cross-contamination risk
Research & Development

Blackstone and Novartis: Joint venture targets cardiovascular disease

Anthos Therapeutics enters the market with US$250 million backing from Blackstone and an anti-thrombotic licensed from Novartis
Ingredients

Therapeutics: anticancer agent: alpelisib

Phosphoinositide 3-kinase enzymes are a group of intracellular signal transducers that phosphorylate the 3-hydroxyl group of phosphatidylinositol
Subscribe now